Key Insights

Highlights

Success Rate

79% trial completion

Published Results

57 trials with published results (11%)

Research Maturity

184 completed trials (34% of total)

Clinical Risk Assessment

Based on trial outcomes

High Risk

Score: 62/100

Termination Rate

9.2%

49 terminated out of 534 trials

Success Rate

79.0%

-7.6% vs benchmark

Late-Stage Pipeline

3%

17 trials in Phase 3/4

Results Transparency

31%

57 of 184 completed with results

Key Signals

57 with results79% success49 terminated

Data Visualizations

Phase Distribution

386Total
Not Applicable (129)
Early P 1 (30)
P 1 (119)
P 2 (91)
P 3 (14)
P 4 (3)

Trial Status

Completed184
Recruiting127
Unknown87
Terminated49
Not Yet Recruiting32
Active Not Recruiting25

Trial Success Rate

79.0%

Benchmark: 86.5%

Based on 184 completed trials

Clinical Trials (534)

Showing 20 of 20 trials
NCT03796273Early Phase 1Terminated

Ketoconazole Before Surgery in Treating Patients With Recurrent Glioma or Breast Cancer Brain Metastases

NCT07628634Early Phase 1Recruiting

Feasibility Study on the Effect of a Methionine-Reduced Diet on Serum Levels in Pts w/ Solid Tumors

NCT02465060Phase 2Active Not Recruiting

Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

NCT05355701Phase 1Recruiting

A Study to Learn About the Study Medicine Called PF-07799933 in People With Advanced Solid Tumors With BRAF Alterations.

NCT07464925Phase 1Recruiting

A Phase 1 Safety and Dose Finding Study of GLIX1 in Adults With Recurrent or Progressive High-grade Glioma

NCT07416188Phase 1Recruiting

Novel Indenoisoquinolone CMYC/TOPOISOMERASE 1 Inhibitor (LMP744) in Recurrent Glioblastoma

NCT07076498Phase 1RecruitingPrimary

Engineered HSV-1 M032 for the Treatment of Children and Adults With Newly Diagnosed Diffuse Midline Glioma After Standard of Care Radiation

NCT06161519Phase 1RecruitingPrimary

PLX038 in Primary Central Nervous System Tumors Containing MYC or MYCN Amplifications

NCT05538130Phase 1Recruiting

A Study to Learn About the Study Medicine Called PF-07799544 as Monotherapy or in Combination in People With Advanced Solid Tumors

NCT03030066Phase 1CompletedPrimary

Study of DS-1001b in Patients With Gene IDH1-Mutated Gliomas

NCT03180502Phase 2Active Not Recruiting

Proton Beam or Intensity-Modulated Radiation Therapy in Preserving Brain Function in Patients With IDH Mutant Grade II or III Glioma

NCT07725640Not ApplicableNot Yet RecruitingPrimary

Feasibility Assessment of a Medical Device for Tumour Cell Retention and Radiotherapy Sensitization in Patients With Suspected High-grade Glioma

NCT05592743UnknownPrimary

Vorasidenib Expanded Access Program

NCT07703605Not Yet Recruiting

AI-Assisted MRI Molecular Subtyping in Pediatric Brain Tumors

NCT07326566Phase 2Recruiting

Study of Silevertinib With Temozolomide for the Treatment of Newly Diagnosed GBM With Unmethylated MGMT and EGFRvIII

NCT04521686Phase 1Active Not Recruiting

Study of LY3410738 Administered to Patients With Advanced Solid Tumors With IDH1 or IDH2 Mutations

NCT05188508Phase 2RecruitingPrimary

Pembrolizumab, Olaparib, and Temozolomide for People With Glioma

NCT07717827Recruiting

Connectome-guided Onco-functional Resection With Tractography-Extended Neuronavigation in Brain Tumor Surgery

NCT07488780Not ApplicableNot Yet RecruitingPrimary

Language Network Prehab Via fMRI Neurofeedback

NCT06413706Phase 2Active Not RecruitingPrimary

A Study Comparing Abemaciclib Plus Temozolomide to Temozolomide Monotherapy in Children and Young Adults With High-grade Glioma Following Radiotherapy

Scroll to load more

Research Network

Activity Timeline